1 The pharmacology of the acute hyperthermia that follows 3,4-methylenedioxymethamphetamine (MDMA,`ecstasy') administration to rats has been investigated. 2 MDMA (12.5 mg kg 71 i.p.) produced acute hyperthermia (measured rectally). The tail skin temperature did not increase, suggesting that MDMA may impair heat dissipation. 
Introduction
3,4-Methylenedioxymethamphetamine (MDMA or`ecstasy') is a commonly used recreational drug, often ingested at dance clubs. A major feature of cases presenting with acute MDMA toxicity is hyperthermia, with body temperatures as high as 438C having been reported (Henry, 1992) . It is probable that many of the other, often fatal, toxicological problems that are seen, particularly rhabdomyolysis, disseminated intravenous coagulation and acute renal failure (Brown & Osterloh, Surprisingly, there has been limited experimental investigation into the pharmacology of the MDMA-induced acute hyperthermic response, despite the fact that administration of MDMA to rats, as in humans, produces an acute dosedependent hyperthermic response (Nash et al., 1988; Gordon et al., 1991; Colado et al., 1993; Dafters, 1994; O'Shea et al., 1998) . It has long been known that acutely increasing 5-HT synthesis and release in rat brain by administration of Ltyrptophan and a monoamine oxidase inhibitor results in hyperthermia (Grahame-Smith, 1971a; Green & GrahameSmith, 1976) . Since MDMA produces an acute and massive release of 5-HT from serotonergic nerve endings (Stone et al., 1986; Schmidt et al., 1987; Colado & Green, 1994; Mechan et al., 2000) it has sometimes been assumed (e.g. Shankaran & Gudelsky, 1999 ) that MDMA-induced hyperthermia is a consequence of 5-HT release and subsequent stimulation of the 5-HT receptors involved in thermoregulation. Such a view has been reinforced by the observations that p-chloroamphetamine, another 5-HT releasing drug, also produces hyperthermia and that 5-HT 2 receptor antagonists such as ketanserin and MDL 11,939 antagonize MDMA-induced hyperthermia (Nash et al., 1988; Schmidt et al., 1990) .
One problem encountered in previous studies on MDMAinduced neurotoxicity has been the fact that some drugs produce marked hypothermia in rats when given alone. This eect therefore confounds any evidence that a drug has a selective action on the MDMA-induced hyperthermic response and makes interpretation dicult (see for example Colado et al., 1999) . We have now investigated the eect of compounds known to alter either 5-HT or dopamine function on their ability to antagonize MDMA-induced hyperthermia by examining their eect on both saline and MDMA treated rats.
Methods

Animals
Male Dark Agouti (DA) rats, weighing 200 ± 260 g, were used in all experiments (Harlan U.K. Ltd., Bicester, Oxon, U.K. and Interfauna, Barcelona, Spain). The animals were housed in groups of three, at an ambient temperature of 20+28C and a 12 h light/dark cycle (lights on: 0730 h). Both food (B&K Universal Ltd., Aldbrough, Hull, U.K.) and water were freely provided.
All procedures were carried out following approval by the University Experimental Ethics Committee.
Drugs and drug administration
Drugs were administered, intraperitoneally (i.p.) unless otherwise speci®ed. In the antagonist/uptake inhibitor pretreatment studies all compounds were injected 20 min prior to administration of MDMA or saline. In the microdialysis studies¯uoxetine was administered 5 min before and 55 min after the MDMA or saline, while GBR 12,909 was injected 30 min prior to MDMA/saline administration. All drugs were dissolved in normal saline (NaCl 0.9% w v
71
) at a volume of 1 ml kg
, unless otherwise stated, and doses are quoted as the base weight. Methysergide was dissolved in 20% dimethylsulphoxide in normal saline. Ritanserin and MDL 100,907 were dissolved in 2% glacial acetic acid in deionized water. SB 242084 was dissolved in normal saline and citric acid (25 mM, Sigma) containing a saturated solution of b-cyclodextrin (Sigma). GBR 12909 was dissolved in peanut oil and administered s.c. in a volume of 2 ml kg 71 . Drugs were obtained from the following sources: MDMA (Sigma-Aldrich Co. Ltd., Poole, Dorset, U.K., Dr P. Guiry, University College, Dublin and Ministry of Health, Spain); methysergide hydrogen maleate (Novartis International AG, Basel, Switzerland); a-phenyl-1-(2-phenylethyl)-4-piperidinemethanol (MDL 11,939) and R-(+)-7-chloro-8-hydroxy-3-methyl -1 -phenyl -2,3,4,5 -tetrahydro -1H -3-benzapine (SCH 23390) (Tocris Cookson Ltd., Avonmouth, Bristol, U.K.); ritanserin (Janssen Research Foundation, Beerse, Belgium); R-(+)-a-(2,3-dimethoxyphenyl) -1-[2-(4-¯uorophenylethyl)]-4-piperidinemethanol (MDL 100,907) and 6-chloro-5-methyl-1-[2-(2-methylpyridyl-3-oxy)-pyrid-5-yl carbomyl]indoline (SB 242084) (Dr G. Kennett, Vernalis Ltd., Wokingham, U.K.); (cis)-zimeldine and S-(7)-remoxipride hydrochloride (AstraZeneca, R&D SoÈ dertaÈ lje, Sweden); 1-[2-bis(4-¯uorophenyl) methyoxy]ethyl]-4-3-phenylpropyl]piperazine dihydrochloride (GBR 12909) (Sigma Chemical Co., Poole, Dorset, U.K.).
Temperature measurement
Temperature measurement was performed using an MC 8700 thermometer, with digital readout, and a lubricated H-RB3 rectal temperature probe (EXACON A/S, Roskilde, Denmark). Each rat was lightly restrained by hand for approximately 20 s while the probe was inserted approximately 2.5 cm into its rectum and a steady reading was obtained. In one experiment tail temperature was measured on the upper tail region by binding the thermocouple probe to the tail with plastic tape.
Implantation of a microdialysis probe in the hippocampus or striatum
Rats were anaesthetized with sodium pentobarbitone (`EutaLender', 40 mg kg 71 i.p.) and secured in a Kopf stereotaxic frame with the tooth bar at 73.3 mm below the interaural zero. For implantation in the hippocampus, the dialysis probe (3.5 mm6200 mm, Cuprophan) was implanted +2.2 mm from the interaural line, 74.3 mm lateral and 78 mm below the surface of the brain (KoÈ nig & Klippel, 1963) .
For implantation in the striatum, rats were anaesthetized and prepared as above. The dialysis probe was implanted in the right striatum using the following co-ordinates: +7.9 mm from the interaural line, 72.5 mm lateral and 7 mm below the surface of the brain (KoÈ nig & Klippel, 1963) . In both cases probes were secured to the skull as described by Baldwin et al. (1994) .
Measurement of monoamines and their metabolites in the hippocampal and striatal dialysate in tubes containing 5 ml of a solution composed of HClO 4 (0.01 M), cysteine (0.2%) and sodium metabisulphite (0.2%). The ®rst 60 min sample was discarded and the next three 30 min baseline samples collected before starting MDMA perfusion.
5-HT, dopamine and their metabolites were measured in the dialysate by h.p.l.c. with electrochemical detection. The mobile phase consisted of KH 2 PO 4 (0.05 M), octanesulphonic acid (0.4 mM), EDTA (0.1 mM) and methanol (16%), and was adjusted to pH 3 with phosphoric acid, ®ltered and degassed. The¯ow rate was 1 ml min 71 . The h.p.l.c. system consisted of a pump (Waters 510) linked to a manual sample injector (Loop 20 ml, Rheodyne), a stainless steel reversed-phase column (spherisorb ODS2, 5 mm, 15064.6 mm) with a precolumn and a coulometric detector (Coulochem 5100 A) with a 5011 analytical cell. The working electrode potential was set at 400 mV with 500 nA gain. The current produced was monitored via a computer data handling system (AXXIOM 747).
Statistics
Statistical analyses of the temperature data and microdialysis experiments were performed using the statistical computer package BMDP/386 Dynamic (BMDP Statistical Solutions). Data were analysed by two-way analysis of variance (ANOVA) with repeated measures (program 2V) or, where missing values occurred, an unbalanced repeated measures model (program 5V) was used. Both used treatment as the between-subjects factor and time as the repeated measure. ANOVA was performed on both pre-treatment and posttreatment (starting immediately after the ®rst injection) data.
Results
Effect of MDMA on rectal and tail temperature
Administration of MDMA (12.5 mg kg 71 i.p.) produced an approximate 1.58C rise in rectal temperature within 20 min, and this increase was sustained for at least 3 h (Figure 1 , main graph). In contrast, the tail temperature did not rise but was seen to decrease during the period 40 ± 80 min after injection, compared to the pretreatment value, and was overall similar to the control animal values (Figure 1 
Effect of 5-HT uptake inhibitors on MDMA-induced hyperthermia
Pre-treatment with the 5-HT uptake inhibitor zimeldine (10 mg kg
71
) did not alter MDMA-induced hyperthermia and was without eect on the rectal temperature of salineinjected (control) rats (Figure 4) .
A study was also conducted with the 5-HT uptake inhibitor¯uoxetine, using a dierent protocol. Rats that had a microdialysis probe implanted in the hippocampus 24 h earlier were administered¯uoxetine (10 mg kg ). Both rectal temperature and the concentration of 5-HT in the hippocampal dialysate were measured over the following 4 h.
Fluoxetine administration did not alter the MDMAinduced hyperthermic response ( Figure 5a ). However, the major increase in 5-HT concentration in the dialysate produced by MDMA injection was almost totally abolished in rats injected with¯uoxetine ( Figure 5b ). ), the temperature of the MDMA+SCH 23390 group was signi®cantly lower than that of the control group for 120 min post MDMA injection (Figure 6c ). However, even at the highest dose, SCH 23390 pretreatment was without eect on the rectal temperature of control rats (Figure 6c ).
Effect of GBR 12909 on MDMA-induced hyperthermia
Administration of the dopamine uptake inhibitor GBR 12909 (10 mg kg
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) was without eect on MDMA-induced hyperthermia and also had no eect on the temperature of control animals ( Figure 7 ).
Effect of GBR 12909 on MDMA-induced dopamine release from the striatum
A previous in vitro study (Koch & Galloway, 1997) suggested that GBR 12909 markedly attenuated MDMA-induced dopamine release. This observation was dicult to reconcile with the lack of eect of GBR 12909 on MDMA-induced hyperthermia, given the results of the SCH 23390 study which strongly suggested the involvement of dopamine in the hyperthermic response.
We, therefore, decided to examine the eect of GBR 12909 on MDMA-induced dopamine release in vivo, using a microdialysis probe inserted into the striatum.
Following the administration of MDMA there was a marked and sustained increase in concentration of extracellular dopamine (Figure 8 ) and an increase in rectal temperature (data not shown). Pretreatment with GBR 12909 again failed to inhibit the hyperthermic response (data not shown) and also failed to inhibit the MDMA-induced rise in extracellular dopamine. In control animals GBR 12909 produced a modest enhancement in the extracellular concentration of dopamine and its major metabolite homovanillic acid (HVA) (Figure 8 ). , i.p.) or saline. There was no dierence in the basal temperature of the groups. MDMA produced a signi®cant rise in body temperature (F(1,7)=21.04, P50.01) compared with the saline injected group. Ritanserin did not modify the hyperthermic response induced by MDMA (F(1,6)=1.97, n.s.) and did not alter the body temperature of saline treated rats (F(1,6)=3.68, n.s.). Results shown as mean+s.e.mean of 4 ± 5 rats.
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Ecstasy and hyperthermia A.O. Mechan et alDiscussion Any attempt to characterize the hyperthermic response that follows MDMA administration is fraught with diculties in terms of interpretation of data. Following drug injection any eect seen may result from either an action on the key neurotransmitter or, secondarily, on another neurotransmitter which modulates the action of the initiating transmitter. Also, of course, since drugs are administered peripherally, the eect could also occur via a peripheral mechanism such as a change in blood¯ow. There is also the additional problem of elucidating the brain region, or regions, involved in the hyperthermic response. An observed neurotransmitter change in one region may not re¯ect a change in another more functionally relevant region. Nevertheless, even with all these provisos, such studies remain relevant since they give indications as to the best approaches that might be employed clinically to alleviate the life-threatening hyperthermia that can occur in persons overdosing on this commonly used recreational drug.
At the outset it should be emphasized that the dose of MDMA chosen in this investigation is clinically relevant. It has previously been shown that a dose of MDMA of 10 mg kg 71 (a 20% lower dose than in the current study) produced a plasma drug concentration of 6.3 nmol ml 71 45 min later (Colado et al., 1995) . This value is in exactly the same range as the plasma concentrations reported in patients suering acute adverse responses to ingestion of the drug Dowling et al., 1987) . Furthermore, as McCann & Ricaurte (2001) have recently pointed out, the principle of interspecies drug dose scaling (see Mordenti & Chappell, 1989) should always be used when extrapolating from doses in rat studies to those used by humans.
Using interspecies dose scaling, the dose used in this current study is the equivalent to a human (70 kg) taking a dose of MDMA of 560 mg. Given the most recent evidence that many tablets now being ingested contain between 200 ± 300 mg of MDMA (see: www.dancesafe.org), this means that the current study is equivalent to a human ingesting 2 ± 3 tablets, a not unusual recreational dose.
Acutely, MDMA produces a major release of both 5-HT (Schmidt et al., 1986; Stone et al., 1986; Colado & Green, 1994; Mechan et al., 2000) and dopamine (Koch & Galloway, 1997; Sabol & Seiden, 1998; Colado et al., 1999) . Methamphetamine also induces the release of both these neurotransmitters (Schmidt & Gibb, 1985a, b; , i.p.) or saline. There was no dierence in the basal temperature of the groups. MDMA produced a signi®cant rise in body temperature (F(1,6)=70.44, P50.001) compared with the saline-injected group. SB 242084 did not modify the hyperthermic response induced by MDMA (F(1,5)=0.18, n.s.) and did not alter the body temperature of saline-treated rats (F(1,6)=1.24, n.s.). Results shown as mean+ s.e.mean of 3 ± 4 rats.
Ecstasy and hyperthermia A.O. Mechan et al1993) and hyperthermia follows administration to rats of both MDMA (Nash et al., 1988; Gordon et al., 1991; Colado et al., 1993; O'Shea et al., 1998; Dafters, 1994) and methamphetamine (Clark & Lipton, 1986; Bronstein & Hong, 1995) . Hyperthermia also results from administration of the 5-HT releasing drug p-chloroamphetamine , certain 5-HT agonists such as MK 212 (Yamawaki et al., 1983) , 5-methoxy N,N-dimethyltryptamine (GrahameSmith, 1971b) and quipazine (Yamawaki et al., 1983) and after injection of a monoamine oxidase inhibitor and L-tryptophan (Grahame-Smith, 1971a) . Therefore it has often been assumed that MDMA-induced hyperthermia is also 5-HT mediated (see for example: Shankaran & Gudelsky, 1999) . However, since studies with methamphetamine have implicated dopamine in the hyperthermia seen after administration of that compound (Bronstein & Hong, 1995) , there is little reason not to assume that dopamine release could also be involved in the hyperthermic action of MDMA.
MDMA induces dopamine release, at least in the striatum, through several mechanisms. It has been reported to have a direct dopamine-releasing eect via both a calcium-dependent and -independent mechanism at the level of the nerve ending (Crespi et al., 1997; Koch & Galloway, 1997; Yamamoto & Spanos, 1988; Nash & Brodkin, 1991; Johnson et al., 1986; Schmidt et al., 1987) . In addition, the increased 5-HT function resulting from the MDMA-induced 5-HT release has been suggested to stimulate 5-HT 2 receptors thereby further enhancing dopamine release (Nash, 1990; Gudelsky et al., 1994; Schmidt et al., 1990) . Finally, recent evidence also supports a role for MDMA in inhibiting the dopamine uptake carrier (Metzger et al., 1998) . ) produced a rise in rectal temperature of approximately 1.58C in the current study. This is a similar rise to that seen in our other recent studies (O'Shea et al., 1998; Mechan et al., 2001) . We also brie¯y examined the tail skin temperature following this dose and saw no evidence for an increase occurring at the same time as the rise in rectal temperature. A similar lack of increase in tail temperature occurs following a hyperthermia-inducing dose of methamphetamine (Mohaghegh et al., 1997) . These authors interpreted this to indicate that methamphetamine impaired heat dissipation rather than heat conservation, since tail temperature is a major heat gain/heat loss eector mechanism in rats (Grant, 1963) . Thus MDMA may similarly impair heat dissipation mechanisms.
Regardless of whether this mechanistic interpretation is correct or not, our current investigation does not suggest that the acute MDMA-induced release of 5-HT plays a major role in the hyperthermic response. The non-selective 5-HT 1/2 antagonist methysergide was without eect on the hyperthermic response, while the selective 5-HT 2 antagonist MDL 11,939 blocked the MDMA-induced hyperthermia, in agreement with Schmidt et al. (1990) . However, one has to question whether this latter result was due to a lack of receptor selectivitiy of this compound, or its metabolites, given our observation that another potent and selective 5-HT 2 antagonist, ritanserin, was without an eect at a dose of 1 mg kg
71
, a dose that is still approximately 20 times the ED 50 for inhibiting 5-HT 2 mediated behaviour (Goodwin & Green, 1985) . A lack of selectivity might also explain the fact that ketanserin blocks the MDMAinduced hyperthermic eect (Schmidt et al., 1990 ) since this compound is also an eective a 1 -adrenoceptor antagonist (McCall & Schuette, 1984) . The eect of MDL 11,939 does stand out as being unique. All the other 5-HT 2 antagonists in our study failed to antagonize the MDMA-induced hyperthermia, including MDL 100,907 (5-HT 2A antagonist) and SB 242084 (5-HT 2C antagonist).
Therefore, with the exception of MDL 11,939, the 5-HT antagonist studies reported here suggest that 5-HT 2 receptors are not primarily involved in the MDMA-induced hyperthermic response. Supporting this interpretation are the data obtained with 5-HT uptake inhibitors. The 5-HT uptake inhibitor¯uoxetine failed to alter the MDMA-induced hyperthermic response. Since both¯uoxetine and MDMA are metabolized by the same hepatic enzyme (Crewe et al., 1992) , it was conceivable that altered kinetics of one of these two drugs might be suggested as an explanation for this lack of eect. However, a recent study has demonstrated that uoxetine administration does not alter the concentration of MDMA in the brain following its peripheral administration (Sanchez et al., 2001) . Furthermore, administration of the 5-HT uptake inhibitor zimeldine, which is metabolized by an MDMA produced a signi®cant rise in body temperature 40 min after injection (F(1,6)=15.25, P50.01) compared with the saline injected group, which was sustained for over 2 h. Remoxipride did not modify the hyperthermic response induced by MDMA (F(1,6)=0.16, n.s.) and did not alter the body temperature of saline treated rats (F(1,6)=0.29, n.s.). Results shown as mean+s.e.mean of four rats.
(b) MDMA produced a signi®cant rise in body temperature (F(1,6)=8.00, P50.05) compared with the saline injected group. SCH 23390 attenuated the MDMA-induced hyperthermia (F(1,6)=8.80, P50.05) in the interval 60 ± 170 min and failed to alter temperature in saline-treated rats (F(1,6)=4.65, n.s.). Results shown as mean+s.e.mean of four rats. (c) MDMA produced a signi®cant rise in body temperature (F(1,5)=16.37, P50.01) compared with the saline injected group. SCH 23390 abolished the MDMA-induced hyperthermia (F(1,6)=25.62, P50.01) and failed to alter temperature in saline-treated rats (F(1,5)=0.53, n.s.). Results shown as mean+s.e.mean of 3 ± 4 rats.
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Ecstasy and hyperthermia A.O. Mechan et alentirely dierent pathway to¯uoxetine (Cashman et al., 1988) , also had the same lack of eect on MDMA-induced hyperthermia.
Our studies also demonstrated that while¯uoxetine treatment did not alter the hyperthermic response, it had nevertheless esssentially abolished the MDMA-induced 5-HT release in the hippocampus. This region was selected as one in which it was relatively easy to implant a microdialysis probe (in contrast to the hypothalamus, a more rational region for examining the relationship between neurotransmitter function and temperature related changes). While inhibition by¯uoxetine of MDMA-induced 5-HT release has been reported by others (Berger et al., 1992; Schmidt et al., 1990; Malberg et al., 1996) , we think this is the ®rst study to also examine temperature in the same animals. As mentioned above, it is unlikely that the hippocampus is the locus of any 5-HT mediated thermoregulatory response, the fact remains that MDMA has similar actions in all major forebrain regions, including the hypothalamus . It is therefore likely that the changes produced by MDMA and uoxetine in the hippocampus re¯ect changes also occurring in other brain regions. It is also noteworthy that the rise in the extracellular concentration of 5-HT in the hippocampus following MDMA is of a considerably shorter duration than the rise in rectal temperature ( Figure 5 ). This, in addition to the fact that inhibition of the MDMA-induced acute 5-HT release does not alter the hyperthermia, suggests that these events may be unrelated.
The data with zimeldine and¯uoxetine reported here may also have clinical relevance. Liechti & Vollenweider (2000) recently reported that administration of a low dose of MDMA (1.5 mg kg
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) to healthy volunteers resulted in a modest increase in body temperature which was not attenuated by the 5-HT uptake inhibitor citalopram, even though other MDMA-induced physiological changes were inhibited by this compound.
Although our data fail to provide a clear role for 5-HT in the hyperthermic response, the current study does indicate a role for dopamine. Administration of SCH 23390, a D 1 receptor selective antagonist, produced a dose-dependent inhibition of the hyperthermic response. This indicates that MDMA-induced hyperthermia may primarily result from stimulation of D 1 receptors and is consistent with the observation that SCH 23390 also antagonizes methamphetamine-induced hyperthermia (Bronstein & Hong, 1995) .
While the D 2 selective compound remoxipride was without eect on the hyperthermia, D 2 receptors may also be involved in some of the temperature changes seen following MDMA administration under speci®c conditions. For example, administration of MDMA produces hypothermia in rats kept in low ambient temperature conditions (Gordon et al., 1991; Dafters, 1994) while apomorphine, the prototypic D 2 agonist produces hypothermia in rats at normal and low ambient temperature, but hyperthermia at high ambient temperature (Faunt & Crocker, 1987) . It is, therefore, possible that D 2 stimulation predominates in animals adminstered MDMA at ambient temperatures below approxi- mately 188C, which is why hypothermia is then seen in these animals (Gordon et al.; 199l Dafters, 1994) . Similarly, it seems reasonable to propose that the hypothermia observed in the MDMA+SCH 23390 treated rats given the highest dose of SCH 23390 (Figure 7 ) is due to the total blockade of D 1 sites allowing expression of D 2 receptor stimulation by the dopamine released by MDMA. Thus one sees an`apomorphine-like' eect and hypothermic response which is in agreement with Faunt & Crocker (1987) who reported that apomorphine-induced hypothermia could be potentiated by SCH 23390.
Since Koch & Galloway (1997) showed that GBR 12909 prevented MDMA-induced dopamine release in vitro in brain slices and our results suggested that dopamine is the neurotransmitter primarily involved in MDMA-induced hyperthermia, it seemed surprising that pretreatment with the dopamine uptake inhibitor GBR 12909 had no eect on MDMA-induced hyperthermia. However, the current data on the role of the dopamine uptake site in MDMA-induced dopamine release is con¯icting. The data of Koch & Galloway (1997) using an in vitro technique are hard to reconcile with the fact that, in vivo, in uptake inhibitor mazindol failed to block the acute dopamine depeletion which follows administration of the MDMA-related compound methamphetamine (Marek et al., 1990a) .
We therefore decided to examine further the eect of GBR 12909 on MDMA-induced dopamine release in vivo. Nash & Brodkin (1991) had previously studied the eect of GBR 12909 on MDMA-induced dopamine release in vivo but they had infused MDMA directly into the brain which we postulated might have resulted in a dierent eect to that seen when MDMA was given peripherally. We obtained clear evidence that GBR 12909 has no eect on MDMA-induced dopamine release in the rat when both drugs are given peripherally. This is consistent with a recent study in mice which also demonstrated that GBR 12909 had no eect on MDMA-induced dopamine release in vivo . In addition, our experiment explained why (if we assume from our other results that the hyperthermia is dopamine mediated) MDMA-induced hyperthermia was unaected by GBR 12909.
One explanation for the failure of GBR 12909 to block MDMA-induced dopamine release in the current study could be that we gave an insucient dose. While Rothman et al. (1991) suggested that the ED 50 dose for inhibiting the uptake site was 10 mg kg 71 (the dose used in the current study) and Stephens & Yamamoto (1994) previously found this dose to be sucient to block the dopamine releasing eect of methamphetamine, other studies have indicated that a much higher dose of GBR 12909 (45 mg kg 71 ) is required to completely block the dopamine uptake carrier (Nakachi et al., 1995) . Further studies on the role of the dopamine uptake site in MDMA-induced dopamine release are, therefore, clearly required to ®nally determine whether MDMA is or is not transported by the dopamine uptake carrier. However, the fact that a high dose of mazindol (40 mg kg 71 ) failed to block the dopamine-releasing action of methamphetamine (Marek et al., 1990b) does cast some doubt on the role of the dopamine uptake site in the dopamine releasing action of amphetamine compounds.
There are several studies that demonstrate that MDMA, by increasing 5-HT release indirectly increases dopamine release, via an action at 5-HT 2 receptors. For example, it has been shown that co-administration of¯uoxetine and MDMA enhances dopamine release (Koch & Galloway, 1997) , 5-HT 2 receptor antagonists block the MDMA-induced increase in dopamine (Nash, 1990; Schmidt et al., 1992) and 5-HT agonists potentiate dopamine release (Gudelsky et al., 1994) . The question therefore arises as to why MDMA-induced hyperthermia was not altered by administration of either uoxetine or 5-HT 2 antagonists if indeed the hyperthermia results from increased dopamine function as we are proposing. At present the most plausible explanation is that this association between 5-HT and dopamine function has only been demonstrated to occur in the striatum. It is probable that the dopamine release involved with hyperthermia is an event associated with a direct eect of MDMA on release in a dierent brain area, probably the hypothalamus.
In conclusion, we have demonstrated a clear dissociation between MDMA-induced hyperthermia and a change in 5-HT function, particularly that mediated by 5-HT 2 receptors. However, a probable association between an MDMAinduced increase in dopamine release, D 1 receptor activity and the hyperthermia has been demonstrated. This result suggests that administration of a D 1 receptor antagonist could be a logical way to treat patients presenting with an acute and potentially life-threatening MDMA-induced hyperthermia.
